Michael Forster

Michael Forster

Auto-generated profile, based on publicly available information

Michael Forster

Institute of Pharmaceutical Sciences Department of Pharmaceutical/Medicinal Chemistry Eberhard Karls University Tübingen Tübingen Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JPJúlia G B Pedreira
Júlia G B Pedreira
PNPhilipp Nahidino
Philipp Nahidino
MKMark Kudolo
Mark Kudolo
TPTatu Pantsar
Tatu Pantsar
Benedict-Tilman BergerBenedict-Tilman Berger
Benedict-Tilman Berger
EBEliezer J Barreiro
Eliezer J Barreiro

16 January 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
RRRamona Rudalska
Ramona Rudalska
JHJule Harbig
Jule Harbig
MFMichael Forster
Michael Forster
PWPascal Woelffing
Pascal Woelffing
AEAylin Esposito
Aylin Esposito
DDDaniel Dauch
Daniel Dauch
Colorectal cancer (CRC) constitutes the second leading cause of cancer-related death worldwide and advanced CRCs are resistant to targeted therapies, chemotherapies and immunotherapies. p38α (Mapk14) has been suggested as a therapeutic target in CRC; however, available p38α inhibitors only allow for insufficient target inhibition. Here we describe a unique class of p38α inhibitors with ultralong target residence times (designated ULTR-p38i) that robustly inhibit p38α downstream signaling and induce distinct biological phenotypes. ULTR-p38i monotherapy triggers an uncontrolled mitotic entry by activating Cdc25 and simultaneously blocking Wee1. Consequently, CRC cells undergo mitotic catastrophe, resulting in apoptosis or senescence. ULTR-p38i exhibit high selectivity, good pharmaco-kinetic properties and no measurable toxicity with strong therapeutic effects in patient-derived CRC organoids and syngeneic CRC mouse models. Conceptually, our study suggests ultralong-target-residence-time kinase inhibitors as an alternative to covalent inhibitors, which, because of the lack of cysteine residues, cannot be generated for many kinase cancer targets.

24 November 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CGCarmen Carrillo García
Carmen Carrillo García
CBCora Becker
Cora Becker
MFMichael Forster
Michael Forster
SLStefan Lohmann
Stefan Lohmann
PFPatricia Freitag
Patricia Freitag
DSDennis Schade
Dennis Schade

17 September 2026 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
NSNico J. Seidler
Nico J. Seidler
MMMonica R. MacDonald
Monica R. MacDonald
AMAthina A. Moschopoulou
Athina A. Moschopoulou
SCSahba Cunningham
Sahba Cunningham
TWTess M. Weber
Tess M. Weber
DHDavid E. Heppner
David E. Heppner
ZUSAMMENFASSUNG: Selektivität ist eine wichtige Anforderung in der Entwicklung von Kinase‐Inhibitoren und das Erreichen dieser stellt nach wie vor eine große Herausforderung dar. Um neue Wege zur Erzielung von Selektivität zu ebnen, haben wir den ersten p38δ‐Isoform‐selektiven Inhibitor entwickelt, welcher im Vergleich zu bisher existierenden Verbindungen 12000‐fach selektiver ist und zudem ein überlegenes Kinomprofil aufweist. Röntgen‐Kristallstrukturen zeigten, dass diese Moleküle nicht‐kanonische n‐π‐π‐Sandwich Wechselwirkungen eingehen, welche durch einen strukturellen Umbau des P‐loops ermöglicht werden. Strukturelle und funktionale Analyse offenbarte, dass es sich bei den Inhibitoren um sich selbsteinkapselnde Verbindungen handelt, welche aufgrund einer sterischen Kollision die Bindetasche verschließen. Diese Konformation wird durch ein Wasserstoffbrücken‐Netzwerk stabilisiert, welches die p38δ‐spezifische Aminosäure H30 beinhaltet. Diese Arbeit zeigt, wie die Selektivität von Inhibitoren durch gezielte Umgestaltung der Bindetasche erreicht wird, wobei strukturelle Merkmale außerhalb der Bindestelle genutzt werden, die häufig übersehen werden.

22 October 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
NSNico J. Seidler
Nico J. Seidler
MMMonica R. MacDonald
Monica R. MacDonald
AMAthina A. Moschopoulou
Athina A. Moschopoulou
SCSahba Cunningham
Sahba Cunningham
TWTess M. Weber
Tess M. Weber
DHDavid E. Heppner
David E. Heppner

13 July 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
XLXiaojun Julia Liang
Xiaojun Julia Liang
CAClaudia Albertini
Claudia Albertini
TKThales Kronenberger
Thales Kronenberger
ESEkaterina Shevchenko
Ekaterina Shevchenko
ARAlexander Rasch
Alexander Rasch
Matthias GehringerMatthias Gehringer
Matthias Gehringer
The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family comprises five nonreceptor tyrosine kinases─BTK, ITK, BMX, TXK, and TEC─with key roles in immune signaling. Although BTK and ITK have been extensively studied, selective inhibitors for TEC, TXK, and BMX remain scarce. Recently, we identified 7-azaindole-based covalent BMX inhibitors with potent inhibitory activity and robust cellular target engagement but limited selectivity across TEC family members, especially BTK. Here, we describe a new generation of BMX inhibitors designed to exploit subtle structural differences between BMX and BTK by incorporating diverse N-acylamino substituents at the azaindole 5-position or variations at the linker and warhead. Our compounds display subnanomolar BMX potency and improved selectivity over BTK and other TEC kinases. Key compound 11i showed strong cellular target engagement, good in vitro metabolic stability, a favorable kinome profile, and rapid covalent inactivation kinetics, positioning it among the best BMX chemical probes currently available.